Sandoz And Aurobindo Cancel US Deal
Billion-Dollar US Oral Solids And Dermatology Deal Called Off
Executive Summary
Sandoz and Aurobindo have mutually agreed to terminate their billion-dollar agreement that would have seen the Indian company acquire Sandoz’ dermatology and oral solids businesses in the US, citing a delay in FTC approval for the deal.
You may also be interested in...
Aurobindo To Formalize Succession Plan In Dec As MD Readies Exit
Aurobindo will formalize a succession plan in early December as managing director N Govindarajan, who has spent over a decade at the company, is set to move on. Meanwhile, though a settlement has been reached for generic Revlimid launch plans, development of a COVID-19 vaccine with partner Vaxxinity has hit a major roadblock.
$10bn Sandoz Business May Be Sold Or Spun As Novartis Weighs Options
Novartis finally has confirmed plans to begin a strategic review for its Sandoz generics and biosimilars business, following years of conjecture and suggestions from the market. However, the originator stressed that it will take its time with a decision, while underlining that keeping Sandoz is among its choices.
ANI Picks Up US Dermatology Brands From Sandoz
ANI Pharmaceuticals has added to its branded portfolio by acquiring several dermatology brands from Sandoz in the US.